- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Shionogi secures $482m BARDA contract to tackle AMR crisis | 3 | Pharmaceutical Technology | ||
| Mi | Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant | 3 | FiercePharma | ||
| 07.04. | Shionogi USA: ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-Producing Enterobacterales Infections | 214 | Business Wire | Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase... ► Artikel lesen | |
| 03.04. | Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform | 9 | pulse2.com | ||
| 01.04. | ViiV Healthcare: Pfizer steigt aus, Shionogi erhöht Anteil | 27 | Investing.com Deutsch | ||
| 01.04. | Shionogi completes purchase of Pfizer stake in GSK's ViiV Healthcare | 9 | Alliance News | ||
| 24.03. | Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream | 2 | FierceBiotech | ||
| SHIONOGI & CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 10.02. | Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. | 495 | PR Newswire | BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and... ► Artikel lesen | |
| 02.02. | Shionogi & Co. GAAP EPS of ¥188.00, revenue of ¥500B | 8 | Seeking Alpha | ||
| 30.01. | Shionogi & Co., Ltd. Reports Rise In Nine Months Profit | 465 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) reported earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY158.225 billion, or JPY185.91 per share.... ► Artikel lesen | |
| 25.01. | Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership | 25 | Insider Monkey | ||
| 20.01. | Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake | 24 | Seeking Alpha | ||
| 20.01. | Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up | 4 | Pharmaceutical Technology | ||
| 20.01. | Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company | 21 | FiercePharma | ||
| 20.01. | Shionogi stockt Anteil an ViiV Healthcare auf - Pfizer steigt aus | 28 | Investing.com Deutsch | ||
| 22.12.25 | ALS med Radicava to change hands as Shionogi inks $2.5B buyout | 3 | FiercePharma | ||
| 04.12.25 | Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance | 9 | FiercePharma | ||
| 30.10.25 | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | 907 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| 28.10.25 | Shionogi lifts profit outlook on HIV royalties and overseas growth | 24 | Japan Times | ||
| 27.10.25 | Shionogi & Co. H1 Net Profit Rises, But Revenue Slips; Revises Annual Outlook | 631 | AFX News | TOKYO (dpa-AFX) - Shionogi & Company Limited (SGIOF, 4507.T), a Japanese pharmaceutical company, on Monday reported a rise in net profit for the first half, helped by an increase in finance... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 5,370 | +0,75 % | Trulieve Cannabis Corp: Trulieve Cannabis to open Boca Raton shop on April 24 | ||
| WEST PHARMACEUTICAL SERVICES | 216,60 | -1,99 % | West Pharmaceutical Services President And CEO Eric Green To Retire | WASHINGTON (dpa-AFX) - West Pharmaceutical Services, Inc. (WST) announced that Eric Green plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the... ► Artikel lesen | |
| KALA BIO | 0,194 | +3,20 % | KALA BIO, Inc.: Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities | TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation... ► Artikel lesen | |
| SHIONOGI | 17,750 | -3,19 % | Shionogi USA: ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-Producing Enterobacterales Infections | Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase... ► Artikel lesen | |
| CHARLOTTES WEB | 0,500 | -1,96 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results | Anticipated CMMI Medicare Pilot Program Participation, Regulatory Momentum, and Cost Structure Improvements Position Company for Growth and Pathway to Profitability
... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,460 | 0,00 % | Beximco Pharma: Gerichtsanhörung auf nach April verschoben | ||
| LUYE PHARMA | 0,306 | -0,65 % | Citi Cuts Luye Pharma TP to HKD4.3; Price Cuts on Mature Products Weigh More Than Expected | ||
| MIRUM PHARMACEUTICALS | 83,44 | +1,71 % | Cantor Fitzgerald reiterates Mirum Pharmaceuticals stock rating | ||
| PERCHERON THERAPEUTICS | 0,003 | -28,57 % | PERCHERON THERAPEUTICS LIMITED: Results of Entitlement Offer | ||
| AYURCANN | 0,001 | 0,00 % | Red White & Bloom Brands Inc: Red White subsidiary to acquire Ayurcann assets | ||
| KALBE FARMA | 0,040 | -11,11 % | KLBF profit rises 13% in 2025, prepares IDR 500 billion buyback: Strong export lifts KLBF's net profit 13% to ... | ||
| AVANT BRANDS | 0,374 | -5,08 % | Avant Brands Inc.: Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland | KELOWNA, BC / ACCESS Newswire / March 17, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of ultra-premium cannabis products, today announced... ► Artikel lesen | |
| EVEREST MEDICINES | 4,020 | +1,00 % | EVEREST MED (01952): MAJOR AND CONNECTED TRANSACTION ACQUISITION OF THE ENTIRE EQUITY INTEREST IN THE TARGET COMPANY AND ASSIGNMENT OF SHAREHOLDER LOAN | ||
| KOBAYASHI PHARMACEUTICAL | 30,600 | 0,00 % | Kobayashi Pharmaceutical Co., Ltd. Profit Declines In Full Year | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per... ► Artikel lesen | |
| BAYER | 40,760 | -0,07 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.04.2026... ► Artikel lesen |
SHIONOGI & CO LTD ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHIONOGI & CO LTD ADR finden Sie auf Wallstreet Online.